Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Comparison of Two Vaginal Tablets, Produced at Different Sites, in Postmenopausal Women With Atrophic Vaginitis

Phase 1

Completed

Conditions: Menopause
Postmenopausal Vaginal Atrophy

Interventions: Drug: estradiol, 25 mcg

First Posted Date: 2010-03-12

Last Posted Date: 2014-06-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 70

Registration Number: NCT01085877

Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Congenital FXIII Deficiency
Healthy

Interventions: Drug: recombinant factor XIII
Drug: catridecacog

First Posted Date: 2010-03-08

Last Posted Date: 2016-09-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 51

Registration Number: NCT01082406

Locations: 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom

Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin glargine
Drug: insulin aspart

First Posted Date: 2010-03-03

Last Posted Date: 2017-02-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 493

Registration Number: NCT01079234

Locations: 🇬🇧
Novo Nordisk Investigational Site, Welwyn Garden City, United Kingdom

An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide

First Posted Date: 2010-03-01

Last Posted Date: 2014-06-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2033

Registration Number: NCT01077570

Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec

First Posted Date: 2010-02-26

Last Posted Date: 2017-01-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 33

Registration Number: NCT01076634

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

Phase 4

Completed

Conditions: Diabetes Type 2

Interventions: Drug: Insulin-Levemir
Drug: Exenatide-Bayetta
Drug: Insulin-Levemir and Exenatide-Bayetta
Device: SenseWear Pro3® armband
Device: DexCom CGM

First Posted Date: 2010-02-26

Last Posted Date: 2011-06-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 75

Registration Number: NCT01076842

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
🇺🇸
MedStar Research Institute, Washington, District of Columbia, United States

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2010-02-26

Last Posted Date: 2017-03-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 467

Registration Number: NCT01076647

Locations: 🇷🇴
Novo Nordisk Investigational Site, Satu Mare, Romania

Observational Study to Investigate the Occurrence of Bleeding in Postmenopausal Women Treated With Estradiol/NETA for 12 Months

Completed

Conditions: Menopause
Postmenopausal Bleeding

Interventions: Drug: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)

First Posted Date: 2010-02-26

Last Posted Date: 2014-10-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 176

Registration Number: NCT01076621

Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin detemir
Drug: insulin aspart

First Posted Date: 2010-02-24

Last Posted Date: 2017-03-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 456

Registration Number: NCT01074268

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2010-02-15

Last Posted Date: 2017-03-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 460

Registration Number: NCT01068665

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wrexham, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy